Advertisement

Reactions Weekly

, Volume 1469, Issue 1, pp 2–2 | Cite as

Mutant RAS status linked to inferior PFS, OS with panitumumab

News item
  • 40 Downloads

Reference

  1. Bellamy S. Direct Healthcare Professional Communication on the importance of establishing wild-type RAS (exons 2, 3 and 4 of KRAS and NRAS) status before treatment with Vectibix (panitumumab). Internet Document : [5 pages], 8 Aug 2013. Available from: URL: http://www.mhra.gov.uk

Copyright information

© Springer International Publishing Switzerland 2013

Personalised recommendations